Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1/2 11Phase 1 10Phase NA 9Phase 3 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 4

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Melphalan 3Dexamethasone 3Bortezomib 3daratumumab 1Filgrastim 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Amyloidosis × Clear all
NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Janssen Research & Development, LLC

Phase 3 Completed
416 enrolled 28 charts 2 FDA
Plasma cell

Amyloidosis

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01277016 2017-03-10

EMN-03

European Myeloma Network B.V.

Phase 3 Completed
110 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01998503 2013-11-29

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Nanjing University School of Medicine

Phase 3 Completed
56 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡